Can a new injection tame chronic hepatitis b?
NCT ID NCT07771140
First seen Aug 18, 2026 · Last updated Aug 18, 2026
Summary
This early-stage trial is testing an investigational drug called HECN30227, given as an injection, in healthy volunteers and in people with chronic hepatitis B. The study aims to assess the drug's safety, how the body processes it, and its potential to reduce the virus. Participants receive either the drug or a placebo, with some receiving a single dose and others multiple doses.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- HECN30227 injection
- What this could lead to
- If successful, this could lead to a new treatment option for chronic hepatitis B, potentially reducing or clearing the virus.
- What could go wrong
- This is an early-phase trial focused on safety and dosing, so it is too soon to know if the drug will be effective. Possible side effects are still being evaluated.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HBV INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Second Affiliated Hospital of Anhui Medical University
RECRUITINGHefei, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New injection aims to tame chronic hepatitis b
- Massive french study to track virus effects on pregnant women and kids for 7 years
- New blood test could spot liver cancer sooner
- Scientists map liver degeneration at the cellular level
- New hope for hepatitis b patients with normal ALT: TMF drug trial underway
- 5000 hepatitis b patients to be tracked for immune clues